Laboratorios Jaloma's hand sanitizer labeled 62% ethanol contained 32% methanol and was refused at U.S. border.
What happened
FDA tested a batch of Jaloma Antiseptic Hand Sanitizer that was detained and refused admission at the U.S. border. The product was labeled to contain 62% ethanol, but FDA found on average 32% ethanol and 32% methanol. FDA held a July 22, 2020 teleconference with the firm, and the firm recalled the product on July 31, 2020.
What FDA found
FDA found the hand sanitizer contained about 32% methanol instead of the labeled 62% ethanol, so the active ingredient was substituted.
section 501(d)(2) of the FD&C Act, 21 U.S.C. 351(d)(2)The methanol substitution shows the facility's quality assurance was not working under CGMP (current good manufacturing practice).
section 501(a)(2)(B), 21 U.S.C. 351(a)(2)(B)The hand sanitizer is an unapproved new drug because it is not generally recognized as safe and effective and has no FDA approval.
section 505(a), 21 U.S.C. 355(a)The product is dangerous to health when used as labeled because it contains methanol.
section 502(j), 21 U.S.C. 352(j)The label falsely says 62% ethanol and omits methanol, making the labeling false and misleading.
sections 502(a) and 502(e)(1)(A), 21 U.S.C. 352(a), 352(e)(1)(A)The product does not meet the requirements for marketing as a nonprescription drug under section 505G.
section 502(ee), 21 U.S.C. 352(ee)
What FDA wants
FDA asks the firm to respond in writing within 15 working days with a detailed investigation, raw material and supplier lists, U.S. shipment and reconciliation records, batch records, and analytical test results, and to consider a qualified CGMP consultant. If corrections cannot be completed in time, the firm must explain the delay and give a completion schedule.
Who should pay attention
- brands and distributors that buy hand sanitizer from this manufacturer
- U.S. importers and retailers selling consumer hand sanitizers
- quality teams at drug contract manufacturers and repackagers
This is a summary. Read the original letter on fda.gov.